Pubblicazioni

Homepage
Pagine
Pubblicazioni

Blog

Abstract #TPS9145: FoRT 05-BEAT: a Phase II randomized trial comparing atezolizumab versus atezolizumab+bevacizumab as first-line treatment in patients with PD-L1 high advanced/metastatic NSCLC

Autori: Migliorino MR, Landi L, Galetta D, Ricciardi S, Soregaroli D, Minuti G, Montrone M, Marech I, Morabito A, Berardi R, Novello S, Rocco D, Pilotto S, Zanelli F, Bengala C, Delmonte A, Aieta M, Cortinovis D, Cappuzzo F

Abstract #TPS9140: Combi-TED: A Multicenter, Phase II, Open Label, Randomized Trial Evaluating Efficacy Of TEDOPI Plus Docetaxel Or TEDOPI Plus Nivolumab As Second-Line Therapy In Metastatic NSCLC Progressing After First-Line Chemo-Immunotherapy

Autori: Cappuzzo F, Pasello G, Delmonte A, Landi L, Benetti B , Metro G, D’Andrea MR, Gori S, Borra G , Mazzoni F, Verusio C, Pagano M, Giannarelli D, Bonetti A, Maio M, Scimone A, Adamo V

Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.

Autori: Lorenza Landi , Rita Chiari , Marcello Tiseo , Federica D’Incà , Claudio Dazzi , Antonio Chella , Angelo Delmonte , Laura Bonanno , Diana Giannarelli , Diego Luigi Cortinovis , Filippo de Marinis , Gloria Borra , Alessandro Morabito , Cesare Gridelli , Domenico Galetta , Fausto Barbieri , Francesco Grossi , Enrica Capelletto , Gabriele Minuti , Francesca Mazzoni , Claudio Verusio , Emilio Bria , Greta Alì , Rossella Bruno , Agnese Proietti , Gabriella Fontanini , Lucio Crinò Federico Cappuzzo.

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.

Autori: Verzoni E, Cartenì G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, Buti S, Rossetti S, Cognetti F, Rastelli F, Sobrero A, Turci D, Sternberg CN, Porta C, Cappuzzo F, Tortora G, Tassinari D, Panni S, Pazzola A, Surico G, Raimondi A, De Giorgi U, Procopio G, Italian Nivolumab Renal Cell Cancer Early Access Program group.

The transcriptomic profile of CD138+ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged.

Autori: Storti P, Agnelli L, Palma BD, Todoerti K, Marchica V, Accardi F, Sammarelli G, Deluca F, Toscani D, Costa F, Vicario E, Todaro G, Martella E, Neri A, Giuliani N.

FoRT - Fondazione Ricerca Traslazionale